BioCryst Pharmaceuticals Inc
navenibart
HAE prophylaxis
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for navenibart in HAE prophylaxis are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“New positive, interim results from the long‑term, open‑label ALPHA‑SOLAR trial show sustained, robust HAE attack suppression with navenibart administered every three and six months.”